SUV39H1-deficient (SJ25C1)1XX CAR-T cells

**SUV39H1-deficient (SJ25C1)1XX CAR-T cells** are an advanced chimeric antigen receptor (CAR) T-cell therapy where patient-derived T cells are genetically engineered to express the (SJ25C1)1XX CAR, targeting CD19 on B-cell malignancies, and additionally edited to knock out SUV39H1, a histone-3 lysine-9 methyltransferase. This epigenetic modification sustains stem/memory gene expression, enhances metabolic fitness (glycolysis and oxidative phosphorylation), promotes a memory phenotype, increases expansion after repeated stimulations, reduces inhibitory receptors like PD1 and TIM3, limits exhaustion, and improves long-term persistence and tumor rejection upon rechallenge in both hematologic (e.g., NALM-6 leukemia) and solid tumor (e.g., A549 lung) models. Developed through research at Institut Curie, it shows superior effector function compared to standard 4-1BB/CD3ζ CAR-T cells and supports planned clinical trials in liquid and solid cancers.[1][3][5]

Other names

SUV39H1-deficient SJ25C1 CAR-T cellsSUV-39H1-deficient SJ25C1 CAR-T cellsSUV 39H1-deficient SJ25C1 CAR-T cellsSUV39H1-edited (SJ25C1)1XX CAR-T cells